Skip to Content

6,647 Results Found

  • Article
  • Open Access
13 Citations
7,631 Views
17 Pages

New MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists

  • Jean A. Boutin,
  • Anne Bonnaud,
  • Chantal Brasseur,
  • Olivier Bruno,
  • Nolwenn Lepretre,
  • Peter Oosting,
  • Sophie Coumailleau,
  • Philippe Delagrange,
  • Olivier Nosjean and
  • Céline Legros

The search for melatonin receptor agonists and antagonists specific towards one of the receptor subtypes will extend our understanding of the role of this system in relaying circadian information to the body. A series of compounds derived from a hit...

  • Article
  • Open Access
21 Citations
7,818 Views
14 Pages

3 December 2018

As an attractive drug-target, retinoic acid receptor-related orphan receptor-gamma-t (RORγt) has been employed widely to develop clinically relevant small molecular modulators as potent therapy for autoimmune disease and cancer, but its molecul...

  • Feature Paper
  • Review
  • Open Access
13 Citations
6,374 Views
22 Pages

Non-Nucleoside Agonists of the Adenosine Receptors: An Overview

  • Diego Dal Ben,
  • Catia Lambertucci,
  • Michela Buccioni,
  • Aleix Martí Navia,
  • Gabriella Marucci,
  • Andrea Spinaci and
  • Rosaria Volpini

8 October 2019

Potent and selective adenosine receptor (AR) agonists are of pharmacological interest for the treatment of a wide range of diseases and conditions. Among these derivatives, nucleoside-based agonists represent the great majority of molecules developed...

  • Review
  • Open Access
68 Citations
15,479 Views
16 Pages

TFEB Biology and Agonists at a Glance

  • Mingyue Chen,
  • Yashuang Dai,
  • Siyu Liu,
  • Yuxin Fan,
  • Zongxian Ding and
  • Dan Li

5 February 2021

Autophagy is a critical regulator of cellular survival, differentiation, development, and homeostasis, dysregulation of which is associated with diverse diseases including cancer and neurodegenerative diseases. Transcription factor EB (TFEB), a maste...

  • Review
  • Open Access
24 Citations
3,425 Views
20 Pages

11 March 2022

β2-agonists are a group of synthetic phenylethanolamine compounds which are traditionally used for treating bronchospasm. These compounds can also increase skeletal muscle mass and decrease body fat. The illegal use of β2-agonists in food-p...

  • Review
  • Open Access
136 Citations
20,124 Views
18 Pages

TRPV1: Structure, Endogenous Agonists, and Mechanisms

  • Miguel Benítez-Angeles,
  • Sara Luz Morales-Lázaro,
  • Emmanuel Juárez-González and
  • Tamara Rosenbaum

The Transient Receptor Potential Vanilloid 1 (TRPV1) channel is a polymodal protein with functions widely linked to the generation of pain. Several agonists of exogenous and endogenous nature have been described for this ion channel. Nonetheless, det...

  • Review
  • Open Access
328 Citations
32,215 Views
24 Pages

STING Agonists as Cancer Therapeutics

  • Afsaneh Amouzegar,
  • Manoj Chelvanambi,
  • Jessica N. Filderman,
  • Walter J. Storkus and
  • Jason J. Luke

30 May 2021

The interrogation of intrinsic and adaptive resistance to cancer immunotherapy has identified lack of antigen presentation and type I interferon signaling as biomarkers of non-T-cell-inflamed tumors and clinical progression. A myriad of pre-clinical...

  • Review
  • Open Access
43 Citations
18,079 Views
25 Pages

Agonists and Inhibitors of the cGAS-STING Pathway

  • Xiaoxuan Yu,
  • Linxiang Cai,
  • Jingyue Yao,
  • Cenming Li and
  • Xiaoyong Wang

30 June 2024

The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is pivotal in immunotherapy. Several agonists and inhibitors of the cGAS-STING pathway have been developed and evaluated for the treatment of various diseases. The agon...

  • Article
  • Open Access
15 Citations
7,297 Views
16 Pages

Identification of Selective ERRγ Inverse Agonists

  • Jina Kim,
  • Chun Young Im,
  • Eun Kyung Yoo,
  • Min Jung Ma,
  • Sang-Bum Kim,
  • Eunmi Hong,
  • Jungwook Chin,
  • Hayoung Hwang,
  • Sungwoo Lee and
  • Sung Jin Cho
  • + 6 authors

12 January 2016

GSK5182 (4) is currently one of the lead compounds for the development of estrogen-related receptor gamma (ERRγ) inverse agonists. Here, we report the design, synthesis, pharmacological and in vitro absorption, distribution, metabolism, excretion, to...

  • Review
  • Open Access
11 Citations
6,389 Views
25 Pages

Progress Update on STING Agonists as Vaccine Adjuvants

  • Yanru Shen,
  • Weijin Huang,
  • Jianhui Nie and
  • Li Zhang

31 March 2025

Low antigen immunogenicity poses a significant challenge in vaccine development, often leading to inadequate immune responses and reduced vaccine efficacy. Therefore, the discovery of potent immune-enhancing adjuvants is crucial. STING (stimulator of...

  • Review
  • Open Access
192 Citations
19,992 Views
29 Pages

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

  • Leila Motedayen Aval,
  • James E. Pease,
  • Rohini Sharma and
  • David J. Pinato

16 October 2020

Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have been effective in only a small subset of patients and a principal mechanism underlying immune-refractoriness is a ‘cold’ tumour microenvironment, th...

  • Article
  • Open Access
7 Citations
10,546 Views
11 Pages

A Selective Pharmacophore Model for β2-Adrenoceptor Agonists

  • Rui-Juan Xing,
  • Jian Wang,
  • Li Pan and
  • Mao-Sheng Cheng

6 November 2009

β2-Adrenoceptor selectivity is an important consideration in drug design in order to minimize the possibility of side effects. A selective pharmacophore model was developed based on a series of selective β2-adrenoceptor agonists. The best pharmacopho...

  • Review
  • Open Access
9 Citations
11,929 Views
19 Pages

The United States is experiencing the most profound and devastating opioid crisis in history, with the number of deaths involving opioids, including prescription and illegal opioids, continuing to climb over the past two decades. This severe public h...

  • Review
  • Open Access
56 Citations
8,014 Views
17 Pages

Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases

  • Zaza Khuchua,
  • Aleksandr I. Glukhov,
  • Arnold W. Strauss and
  • Sabzali Javadov

4 November 2018

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that bind to DNA and regulate transcription of genes involved in lipid and glucose metabolism. A growing number of studies provide strong evidence that PPARs are the pr...

  • Review
  • Open Access
140 Citations
14,933 Views
14 Pages

GLP-1 Receptor Agonists and Kidney Protection

  • Eulalia Valentina Greco,
  • Giuseppina Russo,
  • Annalisa Giandalia,
  • Francesca Viazzi,
  • Roberto Pontremoli and
  • Salvatore De Cosmo

Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical ma...

  • Review
  • Open Access
5 Citations
8,337 Views
23 Pages

24 September 2025

Glucagon-like peptide-1 (GLP-1) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evide...

  • Systematic Review
  • Open Access
1 Citations
3,846 Views
29 Pages

Dopamine Partial Agonists in Pregnancy and Lactation: A Systematic Review

  • Alexia Koukopoulos,
  • Delfina Janiri,
  • Miriam Milintenda,
  • Sara Barbonetti,
  • Georgios D. Kotzalidis,
  • Tommaso Callovini,
  • Lorenzo Moccia,
  • Silvia Montanari,
  • Marianna Mazza and
  • Gabriele Sani
  • + 4 authors

Background/Objectives: Dopamine partial agonists are drugs initially developed to treat schizophrenia, seeking a double effect of increased dopaminergic transmission in the prefrontal cortex and decrease in the accumbens/striatum. Of these drugs, ari...

  • Article
  • Open Access
801 Views
16 Pages

15 December 2025

Background and Objectives: GLP-1 receptor agonists (GLP-1 RAs; ATC A10BJ) and dual GLP-1/GIP agonist (ATC A10BX16) have expanded rapidly due to strong evidence in type 2 diabetes, obesity and metabolic dysfunction-associated steatotic liver disease (...

  • Article
  • Open Access
3 Citations
3,782 Views
21 Pages

28 September 2024

Biased agonists of G-protein-coupled receptors (GPCRs) have emerged as promising selective modulators of signaling pathways by offering therapeutic advantages over unbiased agonists to minimize side effects. The dopamine D3 receptor (D3R), a pivotal...

  • Review
  • Open Access
8 Citations
2,556 Views
7 Pages

Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?

  • Andrzej Emeryk and
  • Justyna Emeryk-Maksymiuk

30 October 2020

We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, cl...

  • Article
  • Open Access
6 Citations
3,360 Views
13 Pages

Awake Craniotomy in Conscious Sedation: The Role of A2 Agonists

  • Antonio Izzi,
  • Giuseppe Mincolelli,
  • Grazia D’Onofrio,
  • Vincenzo Marchello,
  • Aldo Manuali,
  • Nadia Icolaro,
  • Lucia Mirabella,
  • Anna Riefolo,
  • Barbara Mazzotta and
  • Alfredo Del Gaudio
  • + 2 authors

30 January 2024

Background: In Awake Craniotomy (AC), α2-agonists and remifentanil (clonidine and dexmedetomidine) are used in the preoperative phase and throughout the procedure to combine monitored anesthesia care and local anesthesia. The study aims were to...

  • Article
  • Open Access
7 Citations
2,602 Views
16 Pages

Activation of the Rat α1β2ε GABAA Receptor by Orthosteric and Allosteric Agonists

  • Allison L. Germann,
  • Ariel B. Burbridge,
  • Spencer R. Pierce and
  • Gustav Akk

21 June 2022

GABAA receptors are a major contributor to fast inhibitory neurotransmission in the brain. The receptors are activated upon binding the transmitter GABA or allosteric agonists including a number of GABAergic anesthetics and neurosteroids. Functional...

  • Review
  • Open Access
5,786 Views
21 Pages

Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach

  • Oana Cristina Șeremet,
  • Ciprian Pușcașu,
  • Corina Andrei,
  • Georgiana Nițulescu,
  • Cristina Elena Zbârcea and
  • Octavian Tudorel Olaru

23 October 2025

Glucagon-like peptide-1 receptor (GLP-1R) agonists are injectable peptide-based therapies that have become a focal point in the medical community due to their significant therapeutic efficacy in type 2 diabetes and obesity treatment. Recent advanceme...

  • Article
  • Open Access
1,630 Views
27 Pages

New Insights into Complex PTSD Treatment: Focus on TAAR1 Agonists

  • David-Mandl V. Tseilikman,
  • Vadim E. Tseilikman,
  • Vladislav A. Shatilov,
  • Daria A. Obukhova,
  • Ilya S. Zhukov,
  • Ivan V. Yatsyk,
  • Victoria A. Maistrenko,
  • Vladimir A. Shipelin,
  • Nikita V. Trusov and
  • Jurica Novak
  • + 3 authors

Background/Objectives: The therapeutic potential of selective trace amine-associated receptor 1 (TAAR1) agonists has been established in multiple animal models of depression and anxiety. PTSD is a debilitating psychiatric disorder frequently characte...

  • Review
  • Open Access
61 Citations
18,006 Views
14 Pages

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease

  • Kallirhoe Kalinderi,
  • Vasileios Papaliagkas and
  • Liana Fidani

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the g...

  • Article
  • Open Access
9 Citations
3,686 Views
15 Pages

New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists

  • Manuel Faúndez-Parraguez,
  • Carlos Alarcón-Miranda,
  • Young Hwa Cho,
  • Hernán Pessoa-Mahana,
  • Carlos Gallardo-Garrido,
  • Hery Chung,
  • Mario Faúndez and
  • David Pessoa-Mahana

18 October 2021

The activation of the human cannabinoid receptor type II (CB2R) is known to mediate analgesic and anti-inflammatory processes without the central adverse effects related to cannabinoid receptor type I (CB1R). In this work we describe the synthesis an...

  • Article
  • Open Access
3 Citations
2,756 Views
15 Pages

Indole-2-Carboxamide as an Effective Scaffold for the Design of New TRPV1 Agonists

  • Samuele Maramai,
  • Claudia Mugnaini,
  • Marco Paolino,
  • Aniello Schiano Moriello,
  • Luciano De Petrocellis,
  • Federico Corelli,
  • Francesca Aiello and
  • Antonella Brizzi

5 February 2025

Due to its central role in pain, inflammation, and related disorders, the Transient Receptor Potential (TPR) Vanilloid Type-1 (TRPV1) ion channel represents an attractive target for the development of novel antinociceptive and anti-inflammatory agent...

  • Article
  • Open Access
14 Citations
4,130 Views
19 Pages

Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation

  • Gabriella Marucci,
  • Diego Dal Ben,
  • Catia Lambertucci,
  • Aleix Martí Navia,
  • Andrea Spinaci,
  • Rosaria Volpini and
  • Michela Buccioni

23 February 2021

Alzheimer’s, Parkinson’s, and multiple sclerosis are neurodegenerative diseases related by neuronal degeneration and death in specific areas of the central nervous system. These pathologies are associated with neuroinflammation, which is involved in...

  • Article
  • Open Access
7 Citations
3,710 Views
8 Pages

Effect of Specific Retinoic Acid Receptor Agonists on Noise-Induced Hearing Loss

  • Sang Hyun Kwak,
  • Gi-Sung Nam,
  • Seong Hoon Bae and
  • Jinsei Jung

Noise is one of the most common causes of hearing loss in industrial countries. There are many studies about chemical agents to prevent noise-induced hearing loss (NIHL). However, there is no commercially available drug yet. Retinoic acid is an activ...

  • Article
  • Open Access
5 Citations
4,252 Views
13 Pages

Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches

  • Meimei Chen,
  • Fafu Yang,
  • Jie Kang,
  • Huijuan Gan,
  • Xuemei Yang,
  • Xinmei Lai and
  • Yuxing Gao

Activating Liver X receptors (LXRs) represents a promising therapeutic option for dyslipidemia. However, activating LXRα may cause undesired lipogenic effects. Discovery of highly LXRβ-selective agonists without LXRα activation were...

  • Article
  • Open Access
17 Citations
5,376 Views
12 Pages

Selective ß2-Adrenoceptor Agonists and Relevant Hyperlactatemia: Systematic Review and Meta-Analysis

  • Alina G. Liedtke,
  • Sebastiano A. G. Lava,
  • Gregorio P. Milani,
  • Carlo Agostoni,
  • Viola Gilardi,
  • Mario G. Bianchetti,
  • Giorgio Treglia and
  • Pietro B. Faré

27 December 2019

Selective ß2-agonists have been imputed as potential cause of l-hyperlactatemia since the 1970s. To document the prevalence of hyperlactatemia associated with selective ß2-agonists and to investigate the predisposing factors, we searched...

  • Review
  • Open Access
17 Citations
4,231 Views
15 Pages

PPARγ Agonists: Emergent Therapy in Endometriosis

  • Alexandre Vallée,
  • Jean-Noël Vallée,
  • Alain Le Blanche and
  • Yves Lecarpentier

Endometriosis is one of the major gynecological diseases of reproductive-age women. This disease is characterized by the presence of glands and stroma outside the uterine cavity. Several studies have shown the major role of inflammation, angiogenesis...

  • Review
  • Open Access
2 Citations
2,359 Views
14 Pages

Application of Surface-Enhanced Raman Spectroscopy Combined with Immunoassay for the Detection of Adrenoceptor Agonists

  • Yao Wang,
  • Yubing Jing,
  • Jinbo Cao,
  • Yingying Sun,
  • Kaitong Guo,
  • Xiujin Chen,
  • Zhaozhou Li,
  • Qiaoqiao Shi and
  • Xiaofei Hu

8 June 2024

Rapid, sensitive, and accurate detection of adrenoceptor agonists is a significant research topic in the fields of food safety and public health. Immunoassays are among the most widely used methods for detecting adrenoceptor agonists. In recent years...

  • Review
  • Open Access
34 Citations
9,166 Views
22 Pages

1 January 2023

The κ-opioid receptor (KOR) has recently emerged as an alternative therapeutic target for the development of pain medications, without deleterious side effects associated with the μ-opioid receptor (MOR). However, modulation of KOR is curren...

  • Communication
  • Open Access
1 Citations
3,028 Views
6 Pages

Activation of the α1β2γ2L GABAA Receptor by Physiological Agonists

  • Spencer R. Pierce,
  • Allison L. Germann and
  • Gustav Akk

11 December 2021

The Cl permeable GABAA receptor is a major contributor to cellular inhibition in the brain. The receptor is normally activated by synaptically-released or ambient GABA but is sensitive to a number of physiological compounds such as β-alan...

  • Review
  • Open Access
5 Citations
5,596 Views
16 Pages

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia

  • Paschalis Evangelidis,
  • Konstantinos Tragiannidis,
  • Eleni Gavriilaki and
  • Athanasios Tragiannidis

Immune thrombocytopenia (ITP) in pediatric patients is a common cause of isolated thrombocytopenia. Various pathophysiological mechanisms are implicated in ITP pathogenesis, including the production of autoantibodies against components of platelets (...

  • Review
  • Open Access
47 Citations
12,967 Views
20 Pages

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain

  • Bartosz Rolek,
  • Mateusz Haber,
  • Magdalena Gajewska,
  • Sylwester Rogula,
  • Arkadiusz Pietrasik and
  • Aleksandra Gąsecka

Sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 receptor (GLP-1-R) agonists are novel therapeutic agents used for the management of type 2 diabetes mellitus (T2DM). Recently, large-scale randomized clinical trials have b...

  • Review
  • Open Access
2,884 Views
34 Pages

Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments

  • Jagannath Mondal,
  • Swayam Prabha,
  • Thomas S. Griffith,
  • David Ferguson and
  • Jayanth Panyam

6 November 2025

Targeting Toll-like receptors 7 and 8 (TLR7/8) has emerged as a promising strategy in cancer immunotherapy. TLR7/8 agonists activate robust Th1-type immune responses and bridge innate and adaptive immunity. Further, TLR7/8 agonists can serve as valua...

  • Review
  • Open Access
23 Citations
22,505 Views
11 Pages

The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review

  • Elisa E. Neuchat,
  • Brooke E. Bocklud,
  • Kali Kingsley,
  • William T. Barham,
  • Patrick M. Luther,
  • Shahab Ahmadzadeh,
  • Sahar Shekoohi,
  • Elyse M. Cornett and
  • Alan D. Kaye

Introduction: Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders, characterized by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which is marked by symptoms such...

  • Review
  • Open Access
3 Citations
5,329 Views
22 Pages

STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists

  • Yannick Gabriel Nerdinger,
  • Amanda Katharina Binder,
  • Franziska Bremm,
  • Niklas Feuchter,
  • Niels Schaft and
  • Jan Dörrie

16 September 2025

As cancer incidence continues to rise and conventional therapies remain of limited effectiveness, the search for novel and innovative cancer treatments is ongoing. In recent years, immunotherapies, including checkpoint inhibitors and cell-based appro...

  • Review
  • Open Access
27 Citations
10,452 Views
22 Pages

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

  • Ferenc Sztanek,
  • László Imre Tóth,
  • Attila Pető,
  • Marcell Hernyák,
  • Ágnes Diószegi and
  • Mariann Harangi

Guidelines for the management of obesity and type 2 diabetes (T2DM) emphasize the importance of lifestyle changes, including a reduced-calorie diet and increased physical activity. However, for many people, these changes can be difficult to maintain...

  • Article
  • Open Access
9 Citations
3,609 Views
11 Pages

Synthesis and In Vitro Evaluation of Novel Liver X Receptor Agonists Based on Naphthoquinone Derivatives

  • Tatsuma Nishioka,
  • Kaori Endo-Umeda,
  • Yuki Ito,
  • Akane Shimoda,
  • Atsuko Takeuchi,
  • Chisato Tode,
  • Yoshihisa Hirota,
  • Naomi Osakabe,
  • Makoto Makishima and
  • Yoshitomo Suhara

26 November 2019

We aimed to synthesize novel liver X receptor (LXR) agonists with potent agonist activity and subtype selectivity. Our synthetic scheme started with naphthoquinone derivatives, such as menadione and 2,3-dichloro-1,4-naphthoquinone. We introduced diff...

  • Review
  • Open Access
19 Citations
5,562 Views
19 Pages

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists

  • Fernando Torres Andón,
  • Sergio Leon,
  • Aldo Ummarino,
  • Esther Redin,
  • Paola Allavena,
  • Diego Serrano,
  • Clément Anfray and
  • Alfonso Calvo

Toll-like receptors (TLRs) are natural initial triggers of innate and adaptive immune responses. With the advent of cancer immunotherapy, nucleic acids engineered as ligands of endosomal TLRs have been investigated for the treatment of solid tumors....

  • Article
  • Open Access
17 Citations
3,726 Views
12 Pages

Ribose and Non-Ribose A2A Adenosine Receptor Agonists: Do They Share the Same Receptor Recognition Mechanism?

  • Giovanni Bolcato,
  • Matteo Pavan,
  • Davide Bassani,
  • Mattia Sturlese and
  • Stefano Moro

Adenosine receptors have been a promising class of targets for the development of new therapies for several diseases. In recent years, a renewed interest in this field has risen, thanks to the implementation of a novel class of agonists that lack the...

  • Review
  • Open Access
10 Citations
11,140 Views
21 Pages

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?

  • Miodrag Janić,
  • Sabina Škrgat,
  • Matevž Harlander,
  • Mojca Lunder,
  • Andrej Janež,
  • Anca Pantea Stoian,
  • Mohamed El-Tanani,
  • Viviana Maggio and
  • Manfredi Rizzo

9 December 2024

Chronic respiratory disorders are the third leading cause of mortality globally. Consequently, there is a continuous pursuit of effective therapies beyond those currently available. The therapeutic potential of the glucagon-like peptide-1 (GLP-1) and...

  • Review
  • Open Access
31 Citations
7,479 Views
25 Pages

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate

  • Pilar Pizcueta,
  • Cristina Vergara,
  • Marco Emanuele,
  • Anna Vilalta,
  • Laura Rodríguez-Pascau and
  • Marc Martinell

6 February 2023

Increasing evidence suggests that the peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily, plays an important role in physiological processes in the central nervous system (CNS) and is involv...

  • Review
  • Open Access
5 Citations
6,415 Views
29 Pages

26 December 2024

As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and...

  • Article
  • Open Access
4 Citations
6,999 Views
21 Pages

Structural Requirements of N-Substituted Spiropiperidine Analogues as Agonists of Nociceptin/Orphanin FQ Receptor

  • Pingping Bao,
  • Xiaole Zhang,
  • Hong Ren,
  • Yan Li,
  • Zulin Mu,
  • Shuwei Zhang,
  • Guohui Li and
  • Ling Yang

6 December 2011

The nociceptin/orphanin FQ (NOP) receptor is involved in a wide range of biological functions, including pain, anxiety, depression and drug abuse. Especially, its agonists have great potential to be developed into anxiolytics. In this work, both the...

  • Article
  • Open Access
34 Citations
9,810 Views
24 Pages

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists

  • Piotr Pankiewicz,
  • Marcin Szybiński,
  • Katarzyna Kisielewska,
  • Filip Gołębiowski,
  • Patryk Krzemiński,
  • Izabela Rutkowska-Włodarczyk,
  • Rafał Moszczyński-Pętkowski,
  • Lidia Gurba-Bryśkiewicz,
  • Monika Delis and
  • Mikołaj Matłoka
  • + 12 authors

TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF’s action has been unsuccessful. Several molecules exerting antidepres...

  • Review
  • Open Access
52 Citations
8,282 Views
33 Pages

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy

  • Lingling Huang,
  • Xiaoyan Ge,
  • Yang Liu,
  • Hui Li and
  • Zhiyue Zhang

Toll-like receptors (TLRs) are a class of pattern recognition receptors that play a critical role in innate and adaptive immunity. Toll-like receptor agonists (TLRa) as vaccine adjuvant candidates have become one of the recent research hotspots in th...

of 133